The therapeutic effects of immune blockers in COVID-19, such as IL-6 inhibitors, have raised questions about whether their benefits stem primarily from suppressing inflammation, reducing hypercoagulation, or a combination of both. This evidence concerns the gene IL6 and COVID-19.